Anisley Valenciaga1, Elizabeth G Grubbs2, Kyle Porter3, Paul E Wakely4, Michelle D Williams5, Gilbert J Cote6, Vasyl V Vasko7, Motoyasu Saji1, Matthew D Ringel1. 1. 1 Division of Endocrinology, Diabetes, and Metabolism, The Ohio State University Wexner Medical Center and Arthur G. James Comprehensive Cancer Center , Columbus, Ohio. 2. 2 Department of Surgical Oncology, University of Texas MD Anderson Cancer Center , Houston, Texas. 3. 3 Center for Biostatistics, The Ohio State University , Columbus, Ohio. 4. 4 Department of Pathology, The Ohio State University , Columbus, Ohio. 5. 5 Department of Pathology, University of Texas MD Anderson Cancer Center , Houston, Texas. 6. 6 Department of Endocrine Neoplasia and Hormonal Disorders, University of Texas MD Anderson Cancer Center , Houston, Texas. 7. 7 Department of Pediatrics, Uniformed Services University of the Health Sciences , Bethesda, Maryland.
Abstract
BACKGROUND: The retinoblastoma (RB) transcriptional corepressor 1 protein functions to slow cell-cycle progression. Inactivation of RB by reduced expression and/or hyperphosphorylation allow for enhanced progression through the cell cycle. Murine models develop medullary thyroid carcinoma (MTC) after generalized loss of RB. However, RB expression in MTC has only been evaluated in a small number of tumors, with differing results. The objective of this study was to determine whether reduced expression of RB and/or overexpression of hyperphosphorylated RB predict MTC aggressive behavior. METHODS: Formalin-fixed, paraffin-embedded primary thyroid tumors and lymph node metastases from MTC patients were evaluated for calcitonin, RB, and phosphorylated RB (pRB) expression by immunohistochemistry. Two expert pathologists evaluated the slides in a blinded manner, and the immunohistochemistry results were compared to disease-specific survival as a primary endpoint. RESULTS: Seventy-four MTC samples from 56 patients were analyzed in this study, including 51 primary tumors and 23 lymph node metastases. The median follow-up time was 6.75 years after surgery (range 0.64-24.30 years), and the median primary tumor size was 30 mm (range 6-96 mm). Sixty-six percent of cases were classified as stage IV. RB nuclear expression was diffusely present in 88% of primary tumors and 78% of lymph node metastases. Nuclear pRB expression was present in 22% of primary tumors and 22% of lymph node metastases. On univariate analysis, reduced RB (<75% tumor cell staining) trended with lower MTC-specific survival for primary tumor and metastatic nodes (primary tumor hazard ratio = 3.54 [confidence interval 0.81-15.47], p = 0.08; and lymph node hazard ratio = 4.35 [confidence interval 0.87-21.83], p = 0.05). For primary tumors, multivariable analysis showed that low nuclear RB expression was independently associated with worse disease-specific (p = 0.01) and overall (p = 0.02) survival. pRB levels were not associated with survival for either primary tumor or lymph node metastases. CONCLUSIONS: Reduced RB expression is associated with decreased patient survival in univariate and multivariable analyses, independent from patient age at surgery or advanced TNM stage. Future studies involving larger MTC patient populations are warranted to determine if lower RB expression levels may serve as a biomarker for aggressive disease in patients with MTC.
BACKGROUND: The retinoblastoma (RB) transcriptional corepressor 1 protein functions to slow cell-cycle progression. Inactivation of RB by reduced expression and/or hyperphosphorylation allow for enhanced progression through the cell cycle. Murine models develop medullary thyroid carcinoma (MTC) after generalized loss of RB. However, RB expression in MTC has only been evaluated in a small number of tumors, with differing results. The objective of this study was to determine whether reduced expression of RB and/or overexpression of hyperphosphorylated RB predict MTC aggressive behavior. METHODS:Formalin-fixed, paraffin-embedded primary thyroid tumors and lymph node metastases from MTC patients were evaluated for calcitonin, RB, and phosphorylated RB (pRB) expression by immunohistochemistry. Two expert pathologists evaluated the slides in a blinded manner, and the immunohistochemistry results were compared to disease-specific survival as a primary endpoint. RESULTS: Seventy-four MTC samples from 56 patients were analyzed in this study, including 51 primary tumors and 23 lymph node metastases. The median follow-up time was 6.75 years after surgery (range 0.64-24.30 years), and the median primary tumor size was 30 mm (range 6-96 mm). Sixty-six percent of cases were classified as stage IV. RB nuclear expression was diffusely present in 88% of primary tumors and 78% of lymph node metastases. Nuclear pRB expression was present in 22% of primary tumors and 22% of lymph node metastases. On univariate analysis, reduced RB (<75% tumor cell staining) trended with lower MTC-specific survival for primary tumor and metastatic nodes (primary tumor hazard ratio = 3.54 [confidence interval 0.81-15.47], p = 0.08; and lymph node hazard ratio = 4.35 [confidence interval 0.87-21.83], p = 0.05). For primary tumors, multivariable analysis showed that low nuclear RB expression was independently associated with worse disease-specific (p = 0.01) and overall (p = 0.02) survival. pRB levels were not associated with survival for either primary tumor or lymph node metastases. CONCLUSIONS: Reduced RB expression is associated with decreased patient survival in univariate and multivariable analyses, independent from patient age at surgery or advanced TNM stage. Future studies involving larger MTC patient populations are warranted to determine if lower RB expression levels may serve as a biomarker for aggressive disease in patients with MTC.
Authors: Samuel A Wells; Sylvia L Asa; Henning Dralle; Rossella Elisei; Douglas B Evans; Robert F Gagel; Nancy Lee; Andreas Machens; Jeffrey F Moley; Furio Pacini; Friedhelm Raue; Karin Frank-Raue; Bruce Robinson; M Sara Rosenthal; Massimo Santoro; Martin Schlumberger; Manisha Shah; Steven G Waguespack Journal: Thyroid Date: 2015-06 Impact factor: 6.568
Authors: Matthew J Cecchini; Charles A Ishak; Daniel T Passos; Andrew Warner; David A Palma; Christopher J Howlett; David K Driman; Frederick A Dick Journal: Hum Pathol Date: 2015-09-11 Impact factor: 3.466
Authors: Karin Flicker; Peter Ulz; Harald Höger; Petra Zeitlhofer; Oskar A Haas; Annemarie Behmel; Wolfgang Buchinger; Christian Scheuba; Bruno Niederle; Roswitha Pfragner; Michael R Speicher Journal: Int J Cancer Date: 2011-11-28 Impact factor: 7.396
Authors: Wendy van Veelen; Rob Klompmaker; Martijn Gloerich; Carola J R van Gasteren; Eric Kalkhoven; Ruud Berger; Cornelis J M Lips; Rene H Medema; Jo W M Höppener; Dennis S Acton Journal: Int J Cancer Date: 2009-01-15 Impact factor: 7.396
Authors: George Z Rassidakis; Raymond Lai; Marco Herling; Candy Cromwell; Annette Schmitt-Graeff; L Jeffrey Medeiros Journal: Am J Pathol Date: 2004-06 Impact factor: 4.307
Authors: Huayang Liu; Xing Tang; Arunima Srivastava; Thierry Pécot; Piotr Daniel; Benjamin Hemmelgarn; Stephan Reyes; Nicholas Fackler; Amneet Bajwa; Raleigh Kladney; Christopher Koivisto; Zhong Chen; Qianben Wang; Kun Huang; Raghu Machiraju; Maria Teresa Sáenz-Robles; Paul Cantalupo; James M Pipas; Gustavo Leone Journal: Nat Cell Biol Date: 2015-07-20 Impact factor: 28.824
Authors: María San Román Gil; Javier Pozas; Javier Molina-Cerrillo; Joaquín Gómez; Héctor Pian; Miguel Pozas; Alfredo Carrato; Enrique Grande; Teresa Alonso-Gordoa Journal: Int J Mol Sci Date: 2020-07-13 Impact factor: 5.923
Authors: Anisley Valenciaga; Motoyasu Saji; Lianbo Yu; Xiaoli Zhang; Ceimoani Bumrah; Ayse S Yilmaz; Christina M Knippler; Wayne Miles; Thomas J Giordano; Gilbert J Cote; Matthew D Ringel Journal: JCI Insight Date: 2018-08-23